RESUMEN
We synthesized three novel STAT3 inhibitors (S3iD1-S3iD3) possessing oxoheptanoic residue enabling linkage to HPMA copolymer carrier via a pH-sensitive hydrazone bond. HPMA copolymer conjugates bearing doxorubicin (Dox) and our STAT3 inhibitors were synthesized to evaluate the anticancer effect of Dox and STAT3 inhibitor co-delivery into tumors. S3iD1-3 and their copolymer-bound counterparts (P-S3iD1-P-S3iD3) showed considerable in vitro cytostatic activities in five mouse and human cancer cell lines with IC50 ~0.6-7.9 µM and 0.7-10.9 µM, respectively. S3iD2 and S3iD3 were confirmed to inhibit the STAT3 signaling pathway. The combination of HPMA copolymer-bound Dox (P-Dox) and P-S3iD3 at the dosage showing negligible toxicity demonstrated significant antitumor activity in B16F10 melanoma-bearing mice and completely cured 2 out of 15 mice. P-Dox alone had a significantly lower therapeutic activity with no completely cured mice. Thus, polymer conjugates bearing STAT3 inhibitors may be used for the chemosensitization of chemorefractory tumors.
Asunto(s)
Doxorrubicina , Metacrilatos , Neoplasias , Ratones , Humanos , Animales , Doxorrubicina/farmacología , Doxorrubicina/uso terapéutico , Neoplasias/tratamiento farmacológico , Ácidos Polimetacrílicos , Concentración de Iones de Hidrógeno , Factor de Transcripción STAT3/metabolismoRESUMEN
BACKGROUND: The treatment of breast cancer has developed a lot during the last decade, nevertheless it still remains a considerable social and economical problem all over the world. The choice of the surgical procedure depends on a patients protocol and the surgeons preferences. The aim of this study is to evaluate the stress on the scar after breast reconstruction. METHODS: Mathematical modeling of the sutured skin flap used for breast implant placement was divided into the following two steps. At first, material model of the selected silicone implant was identified. Afterwards, the mathematical model of the breast and implant was performed. RESULTS: Maximal geometrical deviation for anatomical and round implant is placed on the lower surface of the breast and upper surface of the breast, while in the area of lateral geometry and the area around the nipple the agreement reaches very high level. The maximal tension is located in two median stitches. The maximal force reaches 0.025 N. The Cauchy stress equivalent is located around the nipple and reaches the value of 380 kPa. CONCLUSION: From our results it can be seen, that the anatomical and round breast implants do not result in the same stress on the scar. The maximal value difference reaches 13.4% between stress values for these two breast implants and the round implant results in higher loaded scar compared to the anatomical implant.
Asunto(s)
Implantación de Mama/métodos , Implantes de Mama , Neoplasias de la Mama/cirugía , Cicatriz/patología , Mamoplastia/métodos , Colgajos Quirúrgicos , Abdomen , Implantación de Mama/efectos adversos , Cicatriz/etiología , Femenino , Humanos , Mamoplastia/efectos adversos , Modelos Anatómicos , Modelos EstadísticosRESUMEN
The effects of novel polymeric therapeutics based on water-soluble N-(2-hydroxypropyl)methacrylamide copolymers (P(HPMA)) bearing the anticancer drug doxorubicin (Dox), an inhibitor of ABC transporters, or both, on the viability and the proliferation of the murine monocytic leukemia cell line P388 (parental cell line) and its doxorubicin-resistant subline P388/MDR were studied in vitro. The inhibitor derivatives 5-methyl-4-oxohexanoyl reversin 121 (MeOHe-R121) and 5-methyl-4-oxohexanoyl ritonavir ester (MeOHe-RIT), showing the highest inhibitory activities, were conjugated to the P(HPMA) via the biodegradable pH-sensitive hydrazone bond, and the ability of these conjugates to block the ATP driven P-glycoprotein (P-gp) efflux pump was tested. The P(HPMA) conjugate P-Ahx-NH-NâMeOHe-R121 showed a dose-dependent increase in the ability to sensitize the P388/MDR cells to Dox from 1.5 to 24 µM, and achieved an approximately 50-fold increase in sensitization at 24 µM. The P(HPMA) conjugate P-Ahx-NH-NâMeOHe-RIT showed moderate activity at 6 µM (â¼10 times higher sensitization) and increased sensitization by 50-fold at 12 µM. The cytostatic activity of the P(HPMA) conjugate P-Ahx-NH-NâMeOHe-R121(Dox) containing Dox and the P-gp inhibitor MeOHe-R121, both bound via hydrazone bonds to the P(HPMA) carrier, was almost 30 times higher than that of the conjugate P-Ahx-NH-NâDox toward the P388/MDR cells in vitro. A similar result was observed for P-Ahx-NH-NâMeOHe-RIT(Dox), which exhibited almost 10 times higher cytostatic activity than P-Ahx-NH-NâDox.
Asunto(s)
Transportadoras de Casetes de Unión a ATP/antagonistas & inhibidores , Acrilamidas/síntesis química , Antibióticos Antineoplásicos/farmacología , Doxorrubicina/farmacología , Resistencia a Antineoplásicos , Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/metabolismo , Animales , Línea Celular Tumoral , Sistemas de Liberación de Medicamentos , Hidrazonas/química , Concentración de Iones de Hidrógeno , RatonesRESUMEN
The cytostatic effects of polymeric conjugates based on N-(2-hydroxypropyl)methacrylamide copolymers (PHPMA) and containing doxorubicin bound through amide and hydrazone bonds (mixed conjugates) were compared with the cytostatic effects of monoconjugates containing drug bound through an amide or hydrazone bond. One group of mixed conjugates was formed from two comonomers containing doxorubicin bound to the methacryloyl group through a spacer and an amide (DOX(AM)) or hydrazone (DOX(HYD)) bond via copolymerization with HPMA. A second group of mixed conjugates was formed from two different interconnected HPMA copolymers, one containing DOX(AM) and the other DOX(HYD), forming a high-molecular-weight branched structure. The third mixed polymeric system was a simple mixture of monoconjugates DOX(AM)-PHPMA and DOX(HYD)-PHPMA. Simultaneous treatment with all mixed forms of the polymeric derivatives of doxorubicin significantly increased antitumor efficacy after application of monoconjugates, suggesting a synergizing effect that could be used in designing new doxorubicin-containing therapeutic systems.
Asunto(s)
Acrilamidas/química , Amidas/química , Doxorrubicina/química , Doxorrubicina/farmacología , Hidrazonas/química , Polímeros/química , Animales , Antibióticos Antineoplásicos/química , Antibióticos Antineoplásicos/farmacología , Línea Celular , Línea Celular Tumoral , Humanos , Linfoma de Células T/tratamiento farmacológico , Ratones , Ratones Endogámicos C57BL , Ratones Desnudos , Microscopía Fluorescente , Estructura Molecular , Polímeros/síntesis químicaRESUMEN
The delivery of nitric oxide (NO) specifically to solid tumours was explored in this study as a strategy to augment the passive accumulation of nanomedicines in tumours induced by the Enhanced Permeability and Retention (EPR) effect. An increase in accumulation was achieved by the binding of the chemical precursor of NO, based on an organic nitrate, to a water-soluble synthetic polymer drug carrier. Four structurally different N-(2-hydroxypropyl)methacrylamide (HPMA)-based polymer NO donors were synthesized. Depending on their chemical structure, two of these donors were hydrolytically stable, while two rapidly released the parent nitrate under acidic conditions, mimicking the intracellular environment. The polymer NO donors were shown to overcome the drawbacks related to low-molecular-weight NO releasing compounds, namely systemic toxicity, lack of site specificity, and fast blood clearance. The NO donors showed intracellular NO release upon incubation with tumour cells. In vivo, they potentiated the EPR effect, resulting in an increased accumulation of polymer-bound cytotoxic drug doxorubicin (Dox) in EL4 T-cell lymphoma inoculated in mice. This led to a better therapeutic outcome in the treatment of lymphoma with the high-molecular-weight polymer conjugates carrying Dox but not in the treatment with the free Dox. The localized augmentation of the EPR effect via the tumour-specific NO delivery system can be viewed as a promising strategy to potentiate polymer-based tumour therapy without increasing systemic toxicity.
Asunto(s)
Antibióticos Antineoplásicos/administración & dosificación , Doxorrubicina/administración & dosificación , Portadores de Fármacos/administración & dosificación , Linfoma de Células T/tratamiento farmacológico , Donantes de Óxido Nítrico/administración & dosificación , Polímeros/administración & dosificación , Animales , Línea Celular , Sinergismo Farmacológico , Femenino , Humanos , Ratones Endogámicos C57BLRESUMEN
It has recently been reported that a low intake of calcium may be a risk factor for hypertension. In view of the contradictory results, even when the same survey data base has been used by different researchers, an in-depth analysis was undertaken of the data provided by the two cycles of the National Health and Nutrition Examination Survey (NHANES). Both surveys, conducted in consecutive 4-year intervals during the 1970s, were designed to examine representative samples of the U.S. civilian noninstitutionalized population. The overall descriptive findings in relation to mean blood pressure and calcium intake were virtually identical in the two surveys. Based on "quantile" analysis, neither mean levels of blood pressure nor the prevalence of hypertension was related to calcium intake. Only among black men in NHANES I was a relationship between calcium intake and blood pressure noted. This finding was not apparent among black men in NHANES II or among any of the other sex-race groups in either survey. We conclude that the data of NHANES I and II do not show an association between low calcium intake and blood pressure.
Asunto(s)
Presión Sanguínea , Calcio de la Dieta/administración & dosificación , Hipertensión/etiología , Adulto , Anciano , Población Negra , Femenino , Encuestas Epidemiológicas , Humanos , Masculino , Persona de Mediana Edad , Estados Unidos , Población BlancaRESUMEN
Using data from two national surveys in the United States, the National Hospital Discharge Survey and the National Health Interview Survey, we examined whether the incidence of stroke (based on hospitalization rates), the prevalence of stroke, and disability due to stroke had changed. Discharge rates remained virtually constant from 1970 through 1990. At the same time, the proportion of patients who were treated with surgery or other diagnostic procedures increased from 15 to 57% and the proportion who were discharged dead decreased from 20 to 8%. The data suggest that the incidence has not decreased. Hospitalization rates for stroke have changed very little over the past 20 years. Further, neither the prevalence nor the burden of stroke appear to have increased.
Asunto(s)
Trastornos Cerebrovasculares/mortalidad , Trastornos Cerebrovasculares/terapia , Adulto , Anciano , Anciano de 80 o más Años , Trastornos Cerebrovasculares/epidemiología , Femenino , Mortalidad Hospitalaria , Humanos , Incidencia , Tiempo de Internación , Masculino , Persona de Mediana Edad , Tasa de Supervivencia/tendencias , Estados Unidos/epidemiologíaRESUMEN
N-(2-Hydroxypropyl)methacrylamide (HPMA) copolymer carrier containing the anticancer drug doxorubicin bound either by a proteolytically degradable bond (non-targeted PK1 or targeted with alpha-CD71 mAb) or by a hydrolytically degradable bond were synthesised and tested in vivo for various biological properties. Mouse 38C13 B-cell lympoma was used as a well established and defined cell line for this study. 38C13 cells are sensitive to free doxorubicin and IC50 was very low, about 0.014 microM. PK1 showed a strongly decreased cytostatic effect, IC50 being 12.6 microM. alpha-CD71 targeted conjugate, which can be considered as an antibody-targeted form of PK1, had IC50 0.358 microM. HPMA copolymer with doxorubicin bound via a hydrolytically sensitive bond (HYD conjugate) showed a high cytostatic effect with IC50 about 0.052 microM. We demonstrated that HYD conjugate inhibited DNA synthesis and induced p21(Waf1/Cip1) protein expression (p21(Waf1/Cip1) is cyclin-dependent kinase inhibitor which blocks cell cycle progression) as quickly as free doxorubicin, whereas PK1 acted much more slowly. Similarly, apoptosis induction measured by Annexin V binding and Caspase 3 activity was detected later after incubation of cells with PK1 or alpha-CD71 targeted conjugate. Apoptosis was manifested by elevation of bax and bad mRNA levels, which was much more rapid and intense in the case of free doxorubicin and HYD conjugate. Expression of antiapoptotic genes as well as cyclin-dependent kinases was surprisingly not affected.
Asunto(s)
Acrilamidas/síntesis química , Acrilamidas/farmacología , Doxorrubicina/síntesis química , Doxorrubicina/farmacología , Ligandos , Acrilamidas/metabolismo , Animales , Apoptosis/efectos de los fármacos , Proteínas Portadoras/genética , Proteínas Portadoras/metabolismo , Caspasa 3 , Caspasas/efectos adversos , Caspasas/efectos de los fármacos , Caspasas/metabolismo , Ciclo Celular/genética , Proteínas de Ciclo Celular/genética , Proteínas de Ciclo Celular/metabolismo , Línea Celular Tumoral , Membrana Celular/efectos de los fármacos , Membrana Celular/patología , Proliferación Celular/efectos de los fármacos , Inhibidor p21 de las Quinasas Dependientes de la Ciclina , ADN/antagonistas & inhibidores , ADN/genética , ADN/metabolismo , Doxorrubicina/metabolismo , Evaluación Preclínica de Medicamentos/métodos , Expresión Génica/efectos de los fármacos , Expresión Génica/genética , Genes myc/efectos de los fármacos , Genes myc/genética , Hidrazonas/síntesis química , Hidrazonas/metabolismo , Hidrazonas/farmacología , Hidrólisis , Concentración 50 Inhibidora , Ratones , Proteínas Proto-Oncogénicas c-bcl-2/genética , Proteínas Proto-Oncogénicas c-bcl-2/metabolismo , ARN Mensajero/genética , Receptores de Transferrina/efectos de los fármacos , Receptores de Transferrina/genética , Timidina/metabolismo , Tritio , Proteína X Asociada a bcl-2 , Proteína Letal Asociada a bclRESUMEN
We have synthesized conjugates containing doxorubicin (DOX) bound to oligopeptide side chains (GlyGly or GlyPheLeuGly) of a water-soluble copolymer carrier based on poly[N-(2-hydroxypropyl)methacrylamide] (PHPMA) either through proteolytically (PK1 conjugates) [Synthetic polymeric drugs. U.S. Patent 5,037,883 (1991)] or hydrolytically cleavable bond (HC conjugates). Pharmacological efficacy of PK1 and HC conjugates was compared in vitro on murine: T-cell lymphoma EL4, B-cell leukemia BCL1, B-cell lymphoma 38C13, leukemia P388 and Con A-stimulated A/Ph splenocytes and on human: primary (SW480) and metastatic (SW620) colorectal cancer cell lines parent and transfected with Thy 1.2 gene [2] and on erythromyeloid leukemia cell line K 562. Inhibition of proliferation determined by 3[H]-thymidine incorporation revealed that the cytostatic effect of HC conjugates is up to two orders of magnitude higher compared to PK1 conjugates. In some cancer cell lines (SW 620/T, SW 480) the pharmacological activity of HC conjugates is in vitro comparable with the activity of the free drug. Unlike PK1 conjugates, HC conjugates with a lysosomally degradable spacer (GlyPheLeuGly) are less effective compared to HC conjugates containing lysosomally non-degradable spacer (GlyGly). Moreover, HC conjugates exert pronounced anti-proliferative activity also in erythroblastoid leukemia cell line K 562 with a limited content of lysosomes.
Asunto(s)
Antibióticos Antineoplásicos/química , Doxorrubicina/química , Hidrazonas/química , Lisosomas/química , Neoplasias/tratamiento farmacológico , Animales , Antibióticos Antineoplásicos/administración & dosificación , Doxorrubicina/administración & dosificación , Portadores de Fármacos , Metacrilatos , Ratones , Peso Molecular , Oligopéptidos/administración & dosificación , Oligopéptidos/química , Ácidos Polimetacrílicos , Bazo/citología , Bazo/efectos de los fármacos , Células Tumorales CultivadasRESUMEN
N-(2-Hydroxypropyl)methacrylamide (HPMA) copolymer carrier containing the anticancer drug doxorubicin and targeted with B1 monoclonal antibody (mAb) to BCL1 leukemia cells was synthesised and tested in vitro and in vivo. BCL1 leukemia growing in syngenic Balb/c mice was selected as a tumor model system. B1 mAb recognising the idiotype of surface IgM on BCL1 cells was used as a targeting moiety. Both B1 mAb and doxorubicin were conjugated to HPMA copolymer carrier by aminolysis through a tetrapeptidic Gly-Phe(D,L)-Leu-Gly spacer to ensure the intracellular delivery and controlled release of the drug. B1 mAb-targeted conjugate was shown to possess strictly tumor-specific binding capacity to target BCL1 cells in vitro. A similar conjugate, but containing human nonspecific Ig (HuIg) instead of B1 mAb, failed to bind to BCL1 cells. In vitro, B1 mAb-targeted conjugate demonstrated 40-fold higher cytotoxic effect than nontargeted or human nonspecific Ig-containing HPMA copolymer-bound doxorubicin. Conjugate targeted with B1 mAb was also shown to bind to target BCL1 cells in vivo. B1 mAb-targeted conjugate was shown to be more efficient in the treatment of established BCL1 leukemia than free doxorubicin, nontargeted and human nonspecific Ig-containing conjugate. Antibody-targeted polymeric drugs are thus promising conjugates for cancer treatment.
Asunto(s)
Acrilamidas/uso terapéutico , Antígenos de Neoplasias/inmunología , Doxorrubicina/uso terapéutico , Sistemas de Liberación de Medicamentos/métodos , Leucemia de Células B/tratamiento farmacológico , Acrilamidas/química , Animales , Anticuerpos Antiidiotipos/análisis , Anticuerpos Antiidiotipos/química , Anticuerpos Antiidiotipos/farmacología , Anticuerpos Monoclonales/análisis , Anticuerpos Monoclonales/química , Anticuerpos Monoclonales/farmacología , Peso Corporal/efectos de los fármacos , División Celular/efectos de los fármacos , Línea Celular Tumoral , Doxorrubicina/química , Citometría de Flujo , Hidrogeles/química , Inmunoconjugados/sangre , Inmunoconjugados/farmacología , Inmunoconjugados/uso terapéutico , Concentración 50 Inhibidora , Inyecciones Intraperitoneales , Inyecciones Intravenosas , Leucemia de Células B/inmunología , Leucemia de Células B/mortalidad , Leucocitos Mononucleares/química , Ratones , Ratones Endogámicos BALB C , Recuento de Reticulocitos , Bazo/química , Tasa de SupervivenciaRESUMEN
We present data providing new evidence that poly[N-(2-hydroxypropyl)methacrylamide] (PHPMA)-bound drugs, unlike free drugs, have both cytostatic and immunomobilizing activity (CIA). Immediately after injection, due to the high level of the drug, the main activity of the polymeric conjugate is cytotoxic and cytostatic. Later on, long-term circulating PHPMA-bound drug, at concentrations lower than its minimal inhibitory levels, mobilizes the defense mechanisms of the host. Cytotoxic and cytostatic effects of drug-PHPMA were repeatedly confirmed. The following data support the concept of the immunomobilizing activity of the N-(2-hydroxypropyl)methacrylamide (HPMA) conjugates: (a) pre-treatment with free drugs (doxorubicin, cyclosporin A) accelerates the appearance of EL4 mouse T-cell lymphoma while a similar pre-treatment with doxorubicin-PHPMA induces limited but definitive mobilization of the host's defense mechanisms; (b) mice cured of EL4 mouse T-cell lymphoma, BCL1 mouse B-cell leukemia and 38C13 mouse B-cell lymphoma by injection of doxorubicin-PHPMA conjugate targeted with monoclonal antibodies (anti-Thy 1.2 for EL4, anti-B1 for BCL1 and anti-CD71 for 38C13) and re-transplanted with a lethal dose of the same cancer cells survive without any treatment considerably longer than control mice; (c) increased NK activity and anti-cancer antibody was detected only in animals treated with doxorubicin-PHPMA conjugate; and (d) considerably increased NK and LAK activity was seen in a human patient treated for generalized breast carcinoma with doxorubicin-PHPMA-IgG.
Asunto(s)
Antineoplásicos/administración & dosificación , Sistemas de Liberación de Medicamentos , Metacrilatos/administración & dosificación , Animales , Citotoxicidad Celular Dependiente de Anticuerpos , Neoplasias de la Mama/tratamiento farmacológico , Doxorrubicina/administración & dosificación , Hemangiosarcoma/tratamiento farmacológico , Hemangiosarcoma/inmunología , Células Asesinas Naturales/inmunología , Ratones , Neoplasias Experimentales/tratamiento farmacológico , Neoplasias Experimentales/inmunología , Células Tumorales CultivadasRESUMEN
OBJECTIVE: High levels of hospital expenditures for older people during their last year of life are widely documented. However, evidence of the association between prospectively measured indicators and subsequent hospitalization is sparse. This article investigates the pattern of hospitalization for a sample of Medicare enrollees during their last year of life. DATA SOURCES: Data from the Longitudinal Study of Aging, a national study of persons age 70 and older, are used. Only data on decedents are used. STUDY DESIGN: We determine individual characteristics (including functional status, evidence of disease, living arrangement, and prior hospitalization) shortly before the last year of life. A distinction is made between terminal and nonterminal admissions. National estimates and regression analyses using survey weights are conducted. PRINCIPAL FINDINGS: The likelihood of any use is high regardless of age, functional status, or the presence of major diseases. Although only a few indicators are associated with having a terminal stay, a number of indicators are associated with nonterminal use. Nonterminal stays and total nights hospitalized are positively associated with prior evidence of disease, prior hospitalization, and age, although the probability of nonterminal use decreases with age for persons over 82 years old. The relationship between use and functional status depends on whether persons lived alone, were institutionalized, or had private health insurance. CONCLUSIONS: This study demonstrates that while it is difficult to predict who will be admitted to the hospital at the time of death, a number of characteristics existing before the last year of life are associated with nonterminal hospitalization and total nights hospitalized during the last year of life.
Asunto(s)
Evaluación Geriátrica , Indicadores de Salud , Hospitalización/estadística & datos numéricos , Cuidado Terminal , Factores de Edad , Anciano , Anciano de 80 o más Años , Femenino , Hospitalización/economía , Humanos , Tiempo de Internación , Modelos Logísticos , Estudios Longitudinales , Masculino , Valor Predictivo de las Pruebas , Factores de Riesgo , Encuestas y Cuestionarios , Estados UnidosRESUMEN
N-(2-Hydroxypropyl)methacrylamide (HPMA) copolymers containing the anticancer agent doxorubicin and targeted to the transferrin receptor either with anti-mouse CD71 monoclonal antibody (mAb) or with transferrin were synthesized to evaluate their binding and anti-proliferative activity in vitro and anti-tumor potential against 38C13 B-cell lymphoma in vivo. Both the doxorubicin and the targeting moieties were bound to HPMA copolymer chain by aminolysis via a Gly-Phe(D,L)-Leu-Gly spacer to ensure controlled intracellular release of the conjugated drug. We demonstrated that HPMA copolymer-bound doxorubicin targeted to the transferrin receptor with anti-mouse CD71 mAb strongly retards tumor growth, prolongs the survival and completely cures three out of nine experimental mice with established 38C13 tumors. The conjugate targeted with transferrin was less effective in vitro as well as in vivo. It completely cured only one out of seven experimental mice. Free or non-targeted HPMA copolymer-bound doxorubicin showed only a mild anti-tumor effect within the therapeutic schedule used. In vitro, HPMA copolymer-bound doxorubicin targeted with anti-mouse CD71 mAb shows approximately 4-fold higher cytotoxic effect than HPMA copolymer-bound doxorubicin targeted with transferin and 9-fold higher cytotoxic effect than non-targeted HPMA copolymer-bound doxorubicin.
Asunto(s)
Antibióticos Antineoplásicos/administración & dosificación , Doxorrubicina/administración & dosificación , Linfoma de Células B/metabolismo , Metacrilatos/química , Receptores de Transferrina/efectos de los fármacos , Animales , Antibióticos Antineoplásicos/química , Antibióticos Antineoplásicos/farmacología , Anticuerpos Monoclonales/administración & dosificación , Anticuerpos Monoclonales/química , Biotina/química , División Celular , Doxorrubicina/química , Doxorrubicina/farmacología , Citometría de Flujo , Indicadores y Reactivos , Ligandos , Ratones , Ratones Endogámicos C3H , Receptores de Transferrina/metabolismo , Transferrina/administración & dosificación , Transferrina/químicaRESUMEN
The National Health Interview Survey was administered in 1981 to a national probability sample of approximately 42,000 families. The questions on the Child Health Supplement of the survey were asked about one child in each family that had a child under age 18. The supplement included a series of questions about prescription and nonprescription medications and vitamin and mineral supplements. The respondents supplied information on 15,416 children under age 18. About two-thirds of the children had had some form of medication or vitamin-mineral supplement during any 2-week period in 1981. About one-third of the children were using medications that had been prescribed or recommended by a physician. About 17 percent of the children had been taking medication (excluding vitamin-mineral supplements) daily or nearly every day for the previous 3 months. Use of medications varied by age group. About one-fourth of the children 0-2 years were being given two or more physician-prescribed or -recommended medications or supplements. Use of medications was highest in the first quarter of the year.
Asunto(s)
Vitaminas , Adolescente , Factores de Edad , Niño , Preescolar , Quimioterapia , Humanos , Lactante , Recién Nacido , Estaciones del Año , Encuestas y Cuestionarios , Estados UnidosRESUMEN
By the traditional measures of health status-mortality rates- the health of children in the United States has greatly improved. Fom 1970 to 1979 the infant mortality rate declined from 20.0 to 13.0 per 1,000 live births. The mortality rate per 100,000 children ages 1-4 years declined from 84 to 63. The decline in mortality appears to have been accomplished without a rise in morbidity. Despite the impressive achievements, 10 years after the implementation of Medicaid poor children were still in poorer health than children in families with more money and were still receiving less medical care relative to need. The differentials that existed before the Medicaid program had decreased, but they had not disappeared. If the ideal is that all parents will report that their children are in excellent health and are not limited in activity by any chronic condition, 2 out of 5 children and youths under 18 years of age did not have ideal health in the mid-1970s. Less than half the children in poor or poorly educated families, black children, or children living without fathers in the household achieved that ideal. If a goal for medical care is that children under age 2 have had a contact with a physician within 6 months, children ages 2-5 within a year, and children ages 6-17 within 2 years, 14 percent of U.S. children and youths did not achieve that relatively modest goal. About a quarter of the children in poorly educated families or families with six or more members had not had a contact with a physician that recently. Tooth decay is one of the most prevalent problems of childhood, yet in 1975-76, 38 percent of the children ages 4-17 had not seen a dentist within a year. More than half the children in poorly educated families, black children, or children in low-income families had not seen a dentist that recently.
Asunto(s)
Estado de Salud , Salud , Morbilidad , Atención Individual de Salud/estadística & datos numéricos , Adolescente , Niño , Preescolar , Familia , Femenino , Humanos , Lactante , Mortalidad Infantil , Recién Nacido , Masculino , Factores Sexuales , Factores Socioeconómicos , Factores de Tiempo , Estados UnidosRESUMEN
The oxygen tension (PO2) in the dorsal skin surface of the forearm was studied during the stay of cosmonauts on board Salyut 6. Between the fourth and fifth day of stay on the orbital station a considerable reduction of the PO2 level was observed. The oxygen utilization values were also reduced. In the early postflight period the low PO2 level persisted with gradual normalization.
Asunto(s)
Consumo de Oxígeno/fisiología , Piel/metabolismo , Vuelo Espacial , Ingravidez , Medicina Aeroespacial , Humanos , Masculino , Oxígeno , Presión Parcial , Fenómenos Fisiológicos de la PielRESUMEN
An index of reproductive effiency (RE) is proposed as a social indicator that will meet the need to consider various forms of pregnancy wastage, to compare their relative costs, and to guide reproductive health policy accordingly. This article discusses conceptual and measurement aspects of RE. Conversion of wanted to unwanted pregnancies and the reverse, interpretation of abortion in relation to other pregnancy outcomes, defining the end point for the reproductive process and criteria for the events to be included as significant outcomes are conceptual issues. Measurement problems include: whether aggregation is justified, prospective and retrospective tracking of outcomes, record limitations, duplication of adversities in a single pregnancy, and selection of optimal rate for comparison. A measurement of RE for the entire United States based on the National Natality Survey of 1964-1966 is presented, showing 74.5 percent of pregnancies resulting in healthy liveborn infants. For those years, data on abortions could not be included. Within the group of reported pregnancy losses, the importance of congenital abnormalities and low-birth-weight babies is enhanced by application of economic weights based on associated medical care costs. Changing opportunities for birth timing, prenatal and infant care, and control of family size are social means of reducing adverse outcomes associated with teenage pregnancy and high-parity births, often found together with poverty. Successive increments in RE may be progressively more expensive to achieve, and cost effectiveness comparison will be necessary.
Asunto(s)
Indicadores de Salud , Encuestas Epidemiológicas , Reproducción , Aborto Legal , Tasa de Natalidad , Niño , Economía Médica , Servicios de Planificación Familiar , Femenino , Humanos , Mortalidad Infantil , Recién Nacido , Mortalidad Materna , Embarazo , Embarazo no Deseado , Factores Socioeconómicos , Estados UnidosRESUMEN
In 30 subjects aged 20 to 44 years the functional changes were studied in the gingival capillary bed, pulse rate, systolic and diastolic blood pressure before and during emotional excitation. These values compared, considerable effects were detected suggesting the general circulatory changes and substantial reduction of gingival microcirculation. This indicated that emotional stress-inducing factors may lead to periodontal diseases.